Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19072081 | 0.82 | CA2 (0.47) | CA2CA1TSHRHTTRAB9A | |
| SCHEMBL18737 | 0.79 | — | — | |
| SCHEMBL28817952 | 0.79 | CA1 (0.35) | CA2CA1USP2TSHRHTT | |
| SCHEMBL5892318 | 0.78 | MAPK1 (0.48) | CA2USP2TSHRHTTRAB9A | |
| SCHEMBL18934271 | 0.78 | TSHR (0.46) | CA2CA1USP2TSHRHTT | |
| SCHEMBL8975857 | 0.77 | HTT (0.38) | CA2CA1HTTRAB9AATM | |
| SCHEMBL5134800 | 0.77 | CA2 (0.57) | CA2CA1USP2TSHRMAPK1 | |
| Hydrochloric Acid SCHEMBL530588 | 0.76 | — | — | |
| SCHEMBL3178200 | 0.76 | — | — | |
| SCHEMBL8669520 | 0.76 | CA2 (0.50) | CA2CA1USP2TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20230151034-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20170183346-A1 | SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11bR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11b-HEXAHYDRO-1H-PYRIDO[2,1-a]ISOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) | AGNO PHARMA USA | 2017-06-29 | — | — | US | disclosed |
| US-9295728-B2 | Co-polymer conjugates | NITTO DENKO CORPORATION (JP) | 2016-03-29 | — | — | US | disclosed |
| US-20150152064-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2015-06-04 | — | — | US | disclosed |
| WO-2015077520-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015077521-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| US-20140256660-A1 | ANTIBIOTIC CONJUGATES LINKED WITH STEROID DRUGS | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20130272993-A1 | CO-POLYMER CONJUGATES | NITTO DENKO CORPORATION (JP) | 2013-10-17 | — | — | US | disclosed |
| WO-2011153157-A2 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICAL, INC. (US) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011108744-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, AND RESIST FILM AND PATTERN FORMING METHOD USING THE SAME | FUJIFILM CORPORATION (JP) | 2011-09-09 | — | — | WO | disclosed |
| US-20100168175-A1 | ATPENINS | BAYER CROPSCIENCE AG (DE) | 2010-07-01 | — | — | US | disclosed |
| US-20100168175-A1 | ATPENINS | BAYER CROPSCIENCE AG (DE) | 2010-07-01 | — | — | US | disclosed |
| WO-2010069495-A1 | ATPENINS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2010-06-24 | — | — | WO | disclosed |
| EP-1914070-A1 | Image recording material and lithographic printing plate precursor | FUJIFILM Corporation (JP) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007139856-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| EP-1818340-A1 | GLYCOPEPTIDE ANTIBIOTIC MONOMER DERIVATIVES | National University Corporation Nagoya University (JP) | 2007-08-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151034-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | ASNS, GLUL, GNMT | CA2 3321/4885CA1 1784/4885USP2 1389/4885 |
| US-20140256660-A1 | ANTIBIOTIC CONJUGATES LINKED WITH STEROID DRUGS | CYP21A2, CYP17A1, CYP46A1 | CA2 1831/4885CA1 2586/4885USP2 416/4885 |
| US-20170183346-A1 | SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11bR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11b-HEXAHYDRO-1H-PYRIDO[2,1-a]ISOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) | CYP2S1, CYP26B1, CYP4B1 | CA2 3614/4885CA1 3516/4885USP2 1491/4885 |
| US-20130272993-A1 | CO-POLYMER CONJUGATES | CD44, SLC3A2, SLC7A1 | CA2 2462/4885CA1 785/4885USP2 1556/4885 |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | CA2 4793/4885CA1 4779/4885USP2 2459/4885 |
| US-20150152064-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | EIF2AK2, NSUN3, NSUN2 | CA2 4581/4885CA1 4879/4885USP2 1860/4885 |
| US-20100168175-A1 | ATPENINS | ATP5ME, ATP5MK, ATP5F1B | CA2 4023/4885CA1 4878/4885USP2 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.